The annual Ernst & Young Medical technology report 2015, Pulse of the Industry was released at last week’s AdvaMed 2015 conference and was met with a bit of apprehension. In an interview with MedTech Intelligence, John Babitt, partner, transaction advisory services at Ernst & Young, reviews the key concerns for the medtech industry, along with the areas of opportunity.

Areas of strength include the IPO market, with 43 companies going public in the 12-month period that ended June 30, and 16 mergers and acquisitions deals in excess of $1 billion. The gloom and doom enters in the category of overall single-digit industry growth, which saw only 2% growth, along with the decline in venture capital.